StonvexLoading…
StonvexStonvexStonvexCore line items from RGEN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $738.26M | $634.44M | $632.36M | $801.54M |
Operating Income | $55.17M | $-35.11M | $47.70M | $224.67M |
Net Income | $48.89M | $-25.51M | $35.60M | $185.96M |
EPS (Diluted) | $0.86 | $-0.46 | $0.63 | $3.24 |
Total Assets | $2.95B | $2.83B | $2.83B | $2.53B |
Total Liabilities | $843.57M | $856.95M | $866.34M | $620.90M |
Cash & Equivalents | $566.02M | $757.36M | $751.32M | $523.46M |
Free Cash Flow OCF − CapEx | $93.90M | $149.72M | $77.70M | $87.25M |
Shares Outstanding | 56.33M | 56.09M | 55.77M | 55.56M |